Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618724 | 1.00 | TDP1 (0.44) | TDP1ATMALDH1A1MAPTMAPK1 | |
| SCHEMBL8867114 | 0.86 | HSPB1 (0.44) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL8867121 | 0.86 | HSPB1 (0.44) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL1590012 | 0.82 | MAPK1 (0.44) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL1238283 | 0.82 | MAPK1 (0.44) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL28910907 | 0.81 | MAOA (0.47) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28910908 | 0.81 | MAOA (0.47) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8533307 | 0.80 | ALDH1A1 (0.62) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL6194046 | 0.80 | ALDH1A1 (0.62) | TDP1ALDH1A1MAPTMAPK1NPC1 | |
| SCHEMBL30603181 | 0.80 | ALDH1A1 (0.62) | TDP1ALDH1A1MAPTMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230265-A1 | A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | H. Lundbeck A/S (DK) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091997-A1 | A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | H. LUNDBECK A/S (DK) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168089-A1 | PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | LUNDBECK A/S (DK) | 2016-06-16 | — | — | US | disclosed |
| US-20160168089-A1 | PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | LUNDBECK A/S (DK) | 2016-06-16 | — | — | US | disclosed |
| WO-2016091997-A1 | A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | H. LUNDBECK A/S (DK) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168089-A1 | PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | LUNDBECK A/S (DK) | 2016-06-16 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| EP-2139322-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | Smithkline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118724-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118724-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-0807631-B1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-5981752-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5773618-A | PYRROLOQUINOLINONE DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0807631-A1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168089-A1 | PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE | ADRA2C, QDPR, ADRA1D | TDP1 4199/4885ATM 4528/4885ALDH1A1 309/4885 |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | TDP1 2299/4885ATM 1997/4885ALDH1A1 3293/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | TDP1 2300/4885ATM 2007/4885ALDH1A1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.